Chemomab Therapeutics Ltd DRC (CMMB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $12.31M
Last updated: Nov 17, 2026 at 11:01 AM ET
Chemomab Therapeutics Ltd DRC (CMMB) Competitors
The companies most similar to Chemomab Therapeutics Ltd DRC are CytoMed Therapeutics Limited Ordinary Shares (GDTC), Marker Therapeutics (MRKR) and Quantum BioPharma (QNTM). By market cap, Chemomab Therapeutics Ltd DRC ranks 6th of the 13 companies on this page; Context Therapeutics (CNTX) is the largest at $16.61M.
Peer Comparison
CMMB's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Chemomab Therapeutics Ltd DRC (CMMB) | $12.31M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | $9.90M | N/A | 16.4x | 0.0% | -72.3% | -15.9% | 0.00% |
| Marker Therapeutics Inc (MRKR) | $14.51M | N/A | 14.5x | -245.5% | N/A | -51.0% | 0.00% |
| Quantum BioPharma Ltd. (QNTM) | $10.35M | N/A | N/A | 0.0% | -150.1% | 0.0% | 0.00% |
| Moleculin Biotech Inc (MBRX) | $8.02M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Vyome Holdings, Inc. (HIND) | $11.09M | N/A | N/A | 0.0% | N/A | 67.5% | 0.00% |
| Tempest Therapeutics Inc (TPST) | $7.64M | N/A | N/A | 0.0% | -783.6% | 0.0% | 0.00% |
| Akari Therapeutics PLC (AKTX) | $15.54M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Context Therapeutics Inc (CNTX) | $16.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Fractyl Health, Inc. Common Stock (GUTS) | $11.99M | N/A | N/A | 0.0% | -245.8% | -57.1% | 0.00% |
| FibroBiologics, Inc. Common Stock (FBLG) | $6.57M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Biocardia Inc (BCDA) | $12.58M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Collplant Biotechnologies Ltd (CLGN) | $14.27M | N/A | 21.0x | 0.0% | N/A | -39.7% | 0.00% |
| Peer median | $11.54M | N/A | 16.4x | 0.0% | -197.9% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Chemomab Therapeutics Ltd DRC, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human... | |
| Marker Therapeutics Inc (MRKR) | Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based... | MRKR competitors |
| Quantum BioPharma Ltd. (QNTM) | Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on advancing transformative therapies for oncology and autoimmune diseases. | QNTM competitors |
| Moleculin Biotech Inc (MBRX) | Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant... | MBRX competitors |
| Vyome Holdings, Inc. (HIND) | Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States... | HIND competitors |
| Tempest Therapeutics Inc (TPST) | Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated... | TPST competitors |
| Akari Therapeutics PLC (AKTX) | Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory... | AKTX competitors |
| Context Therapeutics Inc (CNTX) | Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid... | CNTX competitors |
| Fractyl Health, Inc. Common Stock (GUTS) | Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. | GUTS competitors |
| FibroBiologics, Inc. Common Stock (FBLG) | FibroBiologics, Inc. is an innovative biotechnology company dedicated to advancing regenerative medicine through its proprietary fibroblast cell technology... | FBLG competitors |
| Biocardia Inc (BCDA) | BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapies for cardiovascular disease. | BCDA competitors |
| Collplant Biotechnologies Ltd (CLGN) | CollPlant Biotechnologies Ltd., an aesthetic and regenerative medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs... | CLGN competitors |
Frequently Asked Questions About CMMB
Who are Chemomab Therapeutics Ltd DRC's main competitors?
The companies most similar to Chemomab Therapeutics Ltd DRC include CytoMed Therapeutics Limited Ordinary Shares (GDTC), Marker Therapeutics (MRKR), Quantum BioPharma (QNTM), Moleculin Biotech (MBRX) and Vyome Holdings (HIND), listed from the closest match.
Who is Chemomab Therapeutics Ltd DRC's biggest competitor?
Context Therapeutics (CNTX) is the largest of the similar companies at $16.61M; CytoMed Therapeutics Limited Ordinary Shares (GDTC) is the closest match by business profile, size, sector and industry.
How does CMMB stock compare with its competitors?
CMMB's net margin is 0.0% against a peer median of 0.0%.
Which of Chemomab Therapeutics Ltd DRC's competitors pays a higher dividend?
Chemomab Therapeutics Ltd DRC pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Chemomab Therapeutics Ltd DRC bigger than its competitors?
No. Chemomab Therapeutics Ltd DRC is 6th by market cap among the 13 companies on this page; the largest is Context Therapeutics (CNTX) at $16.61M.
CMMB pages: Overview, Earnings, Forecast, Competitors